BR112012012529A2 - composto indol e seu uso farmacêutico - Google Patents

composto indol e seu uso farmacêutico

Info

Publication number
BR112012012529A2
BR112012012529A2 BR112012012529A BR112012012529A BR112012012529A2 BR 112012012529 A2 BR112012012529 A2 BR 112012012529A2 BR 112012012529 A BR112012012529 A BR 112012012529A BR 112012012529 A BR112012012529 A BR 112012012529A BR 112012012529 A2 BR112012012529 A2 BR 112012012529A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical use
indole compound
compound
diseases
indole
Prior art date
Application number
BR112012012529A
Other languages
English (en)
Other versions
BR112012012529B1 (pt
Inventor
Koji Matsumura
Michihide Maekawa
Motoya Suzuki
Ritsuki Masuo
Shinichi Kikuchi
Teruhiko Inoue
Tetsudo Kaya
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of BR112012012529A2 publication Critical patent/BR112012012529A2/pt
Publication of BR112012012529B1 publication Critical patent/BR112012012529B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

composto indol e seu uso farmacêutico a presente invenção provê um agente para o tratamento ou a profilaxia de doenças inflamatórias, doenças alérgicas, doenças autoimunes, rejeição ao transplante ou de condições semelhantes. composto representado pela fórmula [l] abaixo , ou um sal farmaceuticamente aceitável ou solvato ou composto: em que todos os símbolos são , individualmente, tal como definidos no relatório descritivo do pedido de patente.
BR112012012529-0A 2009-11-25 2010-11-25 Composto indol, composição farmacêutica, inibidores e agentes compreendendo o referido composto e seus usos BR112012012529B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009268040 2009-11-25
JP2009-268040 2009-11-25
PCT/JP2010/070988 WO2011065402A1 (ja) 2009-11-25 2010-11-25 インドール化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
BR112012012529A2 true BR112012012529A2 (pt) 2016-05-03
BR112012012529B1 BR112012012529B1 (pt) 2021-10-26

Family

ID=44066507

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012012529-0A BR112012012529B1 (pt) 2009-11-25 2010-11-25 Composto indol, composição farmacêutica, inibidores e agentes compreendendo o referido composto e seus usos

Country Status (31)

Country Link
US (6) US8299070B2 (pt)
EP (3) EP3059234A1 (pt)
JP (6) JP5734628B2 (pt)
KR (1) KR101766502B1 (pt)
CN (1) CN102712624B (pt)
AR (1) AR079164A1 (pt)
AU (1) AU2010323579C1 (pt)
BR (1) BR112012012529B1 (pt)
CA (1) CA2781660C (pt)
CL (1) CL2012001328A1 (pt)
CO (1) CO6541645A2 (pt)
CY (1) CY1117559T1 (pt)
DK (1) DK2505586T3 (pt)
ES (1) ES2572935T3 (pt)
HK (1) HK1174025A1 (pt)
HR (1) HRP20160579T1 (pt)
HU (1) HUE028016T2 (pt)
IL (1) IL220009A (pt)
ME (1) ME02447B (pt)
MX (1) MX2012006017A (pt)
MY (1) MY161095A (pt)
NZ (1) NZ600840A (pt)
PE (1) PE20121358A1 (pt)
PL (1) PL2505586T3 (pt)
PT (1) PT2505586E (pt)
RS (1) RS54910B1 (pt)
RU (1) RU2556216C2 (pt)
SI (1) SI2505586T1 (pt)
SM (1) SMT201600258B (pt)
TW (1) TWI491591B (pt)
WO (1) WO2011065402A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
TW201427664A (zh) 2012-11-02 2014-07-16 Pharmacyclics Inc Ｔｅｃ家族激酶抑制劑佐劑療法
CN103804364A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103800337A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800328A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804361A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804291A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800340A (zh) * 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103804272A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804351A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804302A (zh) * 2012-11-14 2014-05-21 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103804363A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN104628657A (zh) * 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
AR099936A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
ES2748324T3 (es) * 2014-07-04 2020-03-16 Japan Tobacco Inc Método para producir un compuesto de indol
WO2016010108A1 (ja) * 2014-07-18 2016-01-21 塩野義製薬株式会社 含窒素複素環誘導体およびそれらを含有する医薬組成物
CN104356086A (zh) * 2014-11-28 2015-02-18 湖南科技大学 一种适于工业生产3-吗啉酮的制备方法
WO2019225741A1 (ja) 2018-05-25 2019-11-28 日本たばこ産業株式会社 インドール化合物を含むネフローゼ症候群の治療又は予防剤
WO2019225740A1 (ja) 2018-05-25 2019-11-28 日本たばこ産業株式会社 インドール化合物を含む多発性硬化症の治療又は予防剤
AU2019274870A1 (en) 2018-05-25 2020-12-17 Japan Tobacco Inc. Method of treating pain or interstitial cystitis using indole compound
WO2021124155A1 (en) 2019-12-20 2021-06-24 Pfizer Inc. Benzimidazole derivatives
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
WO2022130171A1 (en) * 2020-12-15 2022-06-23 Pfizer Inc. Benzimidazole derivatives and their use as inhibitors of itk for the treatment of skin disease
EP4263538A1 (en) * 2020-12-15 2023-10-25 Pfizer Inc. Pyrido[2,3-d]imidazole derivatives and their use as inhibitors of itk for the teatment of skin disease
CA3217892A1 (en) * 2021-05-03 2022-11-10 Joel Mcintosh Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use
EP4334303A1 (en) * 2021-05-03 2024-03-13 Nurix Therapeutics, Inc. Compounds for inhibiting or degrading itk, compositions, comprising the same methods of their making and methods of their use
TW202315618A (zh) * 2021-06-11 2023-04-16 美商愛德亞生物科學公司 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物
AU2022370351A1 (en) * 2021-10-19 2024-05-02 Nurix Therapeutics, Inc. Bifunctional compounds for degrading itk via ubiquitin proteosome pathway

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US953411A (en) * 1908-09-02 1910-03-29 Erastus De Moulin Trick weight-lifting machine.
EP1441725A1 (en) * 2001-10-26 2004-08-04 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
EP1474425B9 (en) * 2002-01-07 2008-07-02 Eisai Co., Ltd. Deazapurines and uses thereof
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
FR2854159B1 (fr) * 2003-04-25 2008-01-11 Aventis Pharma Sa Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
TWI352705B (en) 2003-09-08 2011-11-21 Aventis Pharma Inc Thienopyrazoles
WO2006112479A1 (ja) * 2005-04-19 2006-10-26 Kyowa Hakko Kogyo Co., Ltd. 含窒素複素環化合物
CA2634061A1 (en) 2005-12-20 2007-07-05 Boehringer Ingelheim International Gmbh 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders
GB0602178D0 (en) 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
CN101437519A (zh) * 2006-03-31 2009-05-20 艾博特公司 吲唑化合物
JP5682051B2 (ja) * 2006-05-18 2015-03-11 ファーマサイクリックス，インク． 細胞内キナーゼ阻害剤
WO2008047831A1 (fr) * 2006-10-17 2008-04-24 Kyowa Hakko Kirin Co., Ltd. Inhibiteurs de JAK
CA2668744C (en) 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
JP2009268040A (ja) 2008-04-23 2009-11-12 Teruhiko Daiho ループアンテナ装置
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof

Also Published As

Publication number Publication date
JP5734628B2 (ja) 2015-06-17
US20180362506A1 (en) 2018-12-20
CA2781660C (en) 2018-06-26
EP2505586A4 (en) 2013-05-15
CN102712624B (zh) 2014-06-04
EP3766877A1 (en) 2021-01-20
CA2781660A1 (en) 2011-06-03
IL220009A (en) 2017-08-31
TW201124378A (en) 2011-07-16
PL2505586T3 (pl) 2016-12-30
ME02447B (me) 2016-09-20
EP3059234A1 (en) 2016-08-24
DK2505586T3 (en) 2016-05-30
RS54910B1 (sr) 2016-10-31
JP2020079276A (ja) 2020-05-28
ES2572935T3 (es) 2016-06-03
CY1117559T1 (el) 2017-04-26
US20210284627A1 (en) 2021-09-16
JP2015172051A (ja) 2015-10-01
CL2012001328A1 (es) 2012-10-05
MY161095A (en) 2017-04-14
CO6541645A2 (es) 2012-10-16
CN102712624A (zh) 2012-10-03
US20170267662A1 (en) 2017-09-21
KR20120096540A (ko) 2012-08-30
MX2012006017A (es) 2012-06-25
HRP20160579T1 (hr) 2016-07-29
US20110306599A1 (en) 2011-12-15
US8299070B2 (en) 2012-10-30
AR079164A1 (es) 2011-12-28
SI2505586T1 (sl) 2016-08-31
JP2011132222A (ja) 2011-07-07
WO2011065402A1 (ja) 2011-06-03
AU2010323579C1 (en) 2016-11-03
PE20121358A1 (es) 2012-10-23
IL220009A0 (en) 2012-07-31
EP2505586B1 (en) 2016-03-02
NZ600840A (en) 2014-01-31
PT2505586E (pt) 2016-06-03
US20130116240A1 (en) 2013-05-09
BR112012012529B1 (pt) 2021-10-26
TWI491591B (zh) 2015-07-11
EP2505586A1 (en) 2012-10-03
RU2556216C2 (ru) 2015-07-10
RU2012126129A (ru) 2013-12-27
KR101766502B1 (ko) 2017-08-08
HK1174025A1 (zh) 2013-05-31
SMT201600258B (it) 2016-08-31
US20200255408A1 (en) 2020-08-13
AU2010323579B2 (en) 2016-05-19
JP2017039761A (ja) 2017-02-23
JP2021091718A (ja) 2021-06-17
AU2010323579A1 (en) 2012-07-19
JP2018158935A (ja) 2018-10-11
HUE028016T2 (en) 2016-11-28

Similar Documents

Publication Publication Date Title
BR112012012529A2 (pt) composto indol e seu uso farmacêutico
PH12014502603A1 (en) D-amino acid compounds for liver disease
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
CU24350B1 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
BR112015019921A2 (pt) composto inibidor de trk
MX2011009847A (es) Agentes antihelminticos y su uso.
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
EA201390198A1 (ru) Гетероциклическое соединение
BR112015014458A8 (pt) compostos derivados de manose, seus intermediários, composição, uso e processos de preparação
PH12015501609A1 (en) Phenicol antibacterials
EA021554B9 (ru) Органические соединения и их применение для лечения hcv инфекции
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
AR086800A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
GT201400050A (es) Derivados de anilina, su preparación y su aplicación terapéutica
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
GT201700220A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)
BR112015013783A2 (pt) quitina ou seus derivados para a prevenção e / ou tratamento de parasitoses
MX2011013869A (es) Agentes antihelminticos y su uso.
CR20160432A (es) Inhibidores de las vías de señalización de wnt
CL2008002060A1 (es) Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.
CR20150327A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
BR112013027395A2 (pt) inibidores de 17alfa-hidroxilase/c17,20-liase
IN2015DN02109A (pt)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: JAPAN TOBACCO INC. (JP)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/11/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.